A groundbreaking experimental treatment using precisely controlled heat could prevent vision loss in millions of people with dry age-related macular degeneration (AMD), according to new research from Aalto University. The technique represents a potential intervention for the dry form of AMD, which accounts for the majority of AMD cases and currently has limited treatment options.
Global Impact of Age-Related Macular Degeneration
Leading causes of vision impairment in adults over 50, millions affected
Source: WHO Global Vision Database, 2025 | Georgian Medical Journal News
Breakthrough in Heat-Based Therapy
Researchers at Aalto University have developed a novel approach using near-infrared light to deliver controlled heat therapy to retinal cells. According to the research, the treatment works by triggering the cells’ natural “cleanup and repair” systems before major damage occurs.
The technique addresses a fundamental problem in dry AMD, where retinal pigment epithelium (RPE) cells gradually lose their ability to maintain the photoreceptors responsible for central vision. Unlike current approaches that attempt to treat damage after it occurs, this method aims to prevent the cellular breakdown entirely.
According to the Aalto University study, the researchers discovered a way to gently heat tissue at the back of the eye using near-infrared light. This represents a significant advancement for patients with dry AMD, who previously had limited treatment options to slow disease progression.
Precision Temperature Control Critical for Success
The success of the treatment depends on achieving precise temperature control within a narrow therapeutic window. The near-infrared laser system delivers energy, a wavelength that penetrates effectively through the eye’s transparent structures while being absorbed specifically by the RPE layer. This targeted approach minimizes heat exposure to other retinal layers and reduces the risk of complications.
Addressing Unmet Medical Need
Age-related macular degeneration affects approximately 196 million people globally, with dry AMD representing the vast majority of cases. The condition progresses slowly over years, with patients experiencing gradual loss of central vision that impacts reading, driving, and facial recognition.
While wet AMD has established treatments including anti-VEGF injections, dry AMD patients have faced a significant treatment gap. The heat therapy approach could potentially be delivered as an outpatient procedure, requiring minimal recovery time and offering a less invasive alternative to current experimental treatments. Research teams are now planning human clinical trials to evaluate both safety and efficacy in real-world patient populations.
Clinical Translation and Future Prospects
The transition from laboratory studies to clinical application requires careful validation of treatment protocols and safety parameters. Researchers must establish optimal timing for intervention, determine patient selection criteria, and develop standardized delivery methods.
Early intervention appears crucial, as the treatment is most effective when RPE cells retain some functional capacity. This timing consideration may require new screening approaches to identify patients in the earliest stages of dry AMD progression.
Regulatory pathways for the device-based therapy may differ from traditional pharmaceutical approaches, potentially accelerating development timelines. The FDA’s medical device approval process could provide a more direct route to clinical availability compared to drug development.
Key takeaways
- New heat therapy targets dry AMD prevention rather than treatment after damage occurs
- Near-infrared laser delivers controlled temperature elevation to activate cellular repair mechanisms
- Technique could address treatment gap for AMD patients who have dry form of disease
- Clinical trials needed to validate safety and efficacy in human patients
Frequently asked questions
How does heat therapy prevent vision loss in AMD?
According to the Aalto University research, the controlled heat triggers the cells’ natural “cleanup and repair” systems, which prevents the cellular breakdown that leads to vision loss in dry AMD.
Is the laser treatment safe for the eye?
The Aalto University study developed a method to gently heat tissue, though human clinical trials are needed to fully establish safety profiles.
When might this treatment become available to patients?
Clinical trials must first validate the approach in humans. If successful, the device-based therapy could potentially reach patients, though timelines depend on regulatory approval processes.
The development of heat-based therapy for dry AMD represents a potential breakthrough in retinal disease prevention. As clinical translation advances, this approach could provide hope for millions of patients facing progressive vision loss, pending successful validation in human trials.
Source: New laser heat treatment could stop blindness before it starts
